drugset

drugset / Trial / NCT02998476

A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)

NCT02998476 ↗

Phase 2 Completed 60 enrolled Incyte Corporation

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and efficacy of parsaclisib in subjects with relapsed or refractory diffuse large B-cell lymphoma.

Timeline

Start: 2017-03-02
Primary completion: 2019-02-22
Completion: 2021-02-05

Publications

Coleman M, Belada D, Casasnovas RO, Gressin R, Lee HP, Mehta A, Munoz J, Verhoef G, Corrado C, DeMarini DJ, Zhao W, Li J, Fay K. Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kdelta inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202). Leuk Lymphoma. 2021 Feb;62(2):368-376. doi: 10.1080/10428194.2020.1832660. Epub 2020 Nov 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Parsaclisib	Small molecule	20 mg	Oral

Indications